trial · primary record
BXCL501 (180 micrograms)
Opioid Use Disorder
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 160 |
| Primary completion | 2027-02-28 |
| Primary endpoint | Safety of BXCL501 versus Placebo and Lofexidine |
| Registry ID | NCT05712707 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:57.402Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05712707
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.